Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘Critical’ Issues Need Resolution Before ICH Q12 Proceeds To Next Step

Executive Summary

Industry and regulatory working group participants are grappling with established conditions and post-approval change management protocols in developing early ICH Q12 draft guidance. Latest proposal calls for three post-approval change categories.

Advertisement

Related Content

ICH Q12 Experts Develop Four-Tier Scheme For Harmonizing Post-Approval Changes
FDA Would Establish Conditions for Swift Manufacturing Changes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel